• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Impact of Malignant Melanoma on Employment and Work Ability

Key Takeaways

  • Malignant melanoma incidence in Germany rose from 3 to 21 cases per 100,000 people annually from 1970 to 2016.
  • Melanoma significantly affects employment, with advanced stages leading to prolonged sick leave and early retirement.
SHOW MORE

The study underscores the importance of addressing work-related concerns for patients with melanoma, advocating for effective communication about rehabilitation options.

Doctor examining patient | Image Credit: © Pixel-Shot - stock.adobe.com

Image Credit: © Pixel-Shot - stock.adobe.com

A recent study found that malignant melanoma has seen a significant rise in incidence, evolving from a relatively rare tumor to the fifth most common solid tumor in Germany by 2015.1 Notably, it exhibits the highest metastasis rate among skin tumors and is responsible for over 90% of skin cancer-related deaths.2 With this in mind, researchers examined the implications of melanoma on employment and work ability, emphasizing the need for rehabilitation strategies tailored to this patient population.

From 1970 to 2016, the age-standardized incidence of melanoma in Germany rose dramatically from 3 to 21 cases per 100,000 people annually. The median age at diagnosis is 63 for women and 69 for men, with notable peaks in young adults (under 30) and individuals over 50. Alarmingly, melanoma is the most prevalent cancer among women aged 20-30, surpassing breast cancer.3 Researchers stated this demographic shift necessitates a thorough understanding of melanoma's impact on the workforce.

Study Methods

The prospective cohort study assessed the changes in employment and work ability among patients with melanoma within the first year post-diagnosis. Researchers focused on the correlation between tumor stage and employment status, analyzing the uptake of rehabilitation services and psycho-oncological support.

Patient Demographics and Findings

A total of 221 patients aged 19 to 65 participated, with a median age of 51. The study revealed a significant association between tumor thickness and the likelihood of engaging in rehabilitation. Specifically, higher tumor stages correlated with greater rates of psycho-oncological consultation. At initial presentation, 28.1% of patients reported being on sick leave, which decreased to 11.1% by the end of the study. However, patients with advanced stages (IIB and above) experienced significantly prolonged sick leave, necessitating a more proactive approach to rehabilitation in these cohorts.

Employment Consequences of Melanoma

Researchers stated that the burden of melanoma extends beyond the clinical realm, affecting patients’ occupational lives significantly. In 2015, melanoma diagnoses led to early retirement for 335 out of every 100,000 individuals under statutory pension insurance in Germany, with a worrying proportion (107) under 50 years old.4 This raises critical questions about how a melanoma diagnosis influences patients' work capacity.

The study found that individuals with melanoma often face prolonged sick leave, particularly following diagnoses at more advanced stages (IIB and above). The psychological toll of a melanoma diagnosis, coupled with the physical consequences of treatment, necessitates effective rehabilitation strategies. Current guidelines in Germany recommend the initiation of rehabilitation measures in primary care settings, recognizing the importance of interdisciplinary approaches to manage the multifaceted challenges faced by patients with melanoma.5

Rehabilitation and Support Services

Despite the potential benefits of rehabilitation, participation rates remain low. In 2020, only 1,887 of approximately 25,000 newly diagnosed patients with melanoma in Germany accessed rehabilitation services. Researchers found common barriers include a lack of awareness regarding available options, administrative hurdles, and insufficient specialized facilities. Notably, the study stated 24% of patients included received psycho-oncological support, yet only 18% accessed rehabilitation services.

The association between tumor stage and the utilization of rehabilitation or psycho-oncological counseling is significant. Patients with thicker tumors were more likely to engage with these services, highlighting a critical need for targeted outreach and education for patients with earlier-stage melanoma.

Implications for Clinical Practice

Researchers stated the findings underscore the necessity for dermatologists and oncologists to address the work-related concerns of patients with melanoma actively. Effective communication about rehabilitation options and early referrals can enhance the quality of life and work capacity for these individuals. Furthermore, understanding the psychological impact of melanoma can guide interventions that support both the mental and physical health of patients.

Conclusion

The study concluded that malignant melanoma poses significant challenges not only in terms of medical management but also regarding the employment and social reintegration of affected individuals. Researchers stated that the high rates of sick leave and the psychological burden associated with the diagnosis highlight the need for robust rehabilitation programs tailored to the specific needs of patients with melanoma. They suggested that future research should focus on developing and validating effective rehabilitation strategies to enhance work ability, particularly in younger adults and those with earlier-stage disease. Enhanced awareness and utilization of available support services are crucial to improving outcomes for this increasingly affected population.

References

  1. Dugas-Breit S, Dugas M, Schulze HJ. Employment, work ability and sick leave in melanoma patients within the first year of diagnosis. J Dtsch Dermatol Ges. Published online October 26, 2024. doi:10.1111/ddg.15560
  2. Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma [published correction appears in Lancet. 2019 Feb 23;393(10173):746. doi: 10.1016/S0140-6736(19)30361-7]. Lancet. 2018;392(10151):971-984. doi:10.1016/S0140-6736(18)31559-9
  3. Cancer in Germany 2019/2020. 14th edition. Robert Koch Institute (ed.) and the Association of Population-based Cancer Registries in Germany (ed.). Published 2022. Accessed October 29, 2024. https://www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_chapters_2019_2020/cancer_germany_2019_2020.pdf?__blob=publicationFile
  4. New pensions because of diminution of ability to work in the Statutory Pension Insurance in the course of the reporting year (number and per 100,000 actively insured persons).Gesundheitsberichterstattung des Bundes. Published 2015. Access October 29, 2024. https://www.gbe-bund.de/gbe/pkg_olap_tables.prc_set_hierlevel?p_uid=gast&p_aid=65986886&p_sprache=E&p_help=2&p_indnr=851&p_ansnr=99858016&p_version=2&p_dim=D.946&p_dw=14498&p_direction=drill
  5. Buhles N, Sander C. Dermatoonkologische rehabilitation [Dermato-oncological rehabilitation]. Hautarzt. 2005;56(7):659-664. doi:10.1007/s00105-005-0958-x
Related Videos
© 2024 MJH Life Sciences

All rights reserved.